Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.

Yu Jun WongPrem Harichander ThurairajahRahul KumarJessica TanKwong Ming FockNgai Moh LawWeiquan LiAndrew KwekYu Bin TanJingyun KohZheng Cong LeeLoshini Senthil KumarEng Kiong TeoTiing-Leong Ang

Published in: Journal of gastroenterology and hepatology (2020)

The SOF/VEL ± RBV is a safe and efficacious treatment option for GT3 HCV patients in a real-world setting. SOF/VEL with RBV may be considered for decompensated GT3 HCV patients.

Keyphrases

end stage renal disease
hepatitis c virus
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
atrial fibrillation